FDA Warns 30 Telehealth Companies Over Illegal Marketing of Compounded GLP-1 Products

On March 3, 2026, the FDA announced it had issued 30 warning letters to telehealth companies for false or misleading claims about compounded GLP-1 products on their websites. March 3, 2026, is the date of the FDA public announcement; secondary reporting dates the letters themselves to February 20, 2026.

According to the FDA, the main violations were claims implying the compounded products were the same as FDA-approved drugs and branding that obscured who actually compounded the products. The agency stated that compounded drugs are not FDA-approved and are not the same as generic drugs.

This was the second telehealth wave on this topic, following a September 2025 wave of warning letters. The pattern across both waves is consistent: the FDA objection is to marketing that presents a compounded product as if it carried the status of an approved drug.

A warning letter is an FDA enforcement step that states the agency position and asks for corrective action. Approval, where it exists in this category, belongs only to a specific approved drug product and its labeled indication, and no compounded GLP-1 product gains that status from a telehealth website claim.